Carcinoma: all 6,715 studies

Page 38 of 68. Open to participants first (1,140), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of UGN-101 in Recurrent PatientsWithdrawnNCT04006691Phase 3
• AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCCCompletedNCT04006405
• Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerStatus unknownNCT04006041Phase 2
• Renal Cell Carcinoma Microenvironment Discovery ProjectCompletedNCT04005183
• Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT04003025
• Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck CancerActive, not recruitingNCT04001543Not applicable
• Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnNCT04001413Phase 2
• PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal CarcinomatosisActive, not recruitingNCT04000906Phase 1
• YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Phase 2
• Application of UCAD for Diagnosing Urothelial Carcinoma.Status unknownNCT03998371
• Study of ET140202 T Cells in Adults With Advanced Hepatocellular CarcinomaTerminatedNCT03998033Phase 1
• TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular CarcinomaStatus unknownNCT03996681Phase 4
• A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular CarcinomaStatus unknownNCT03993743Phase 1
• An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal CancerCompletedNCT03993327Phase 1
• Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaStatus unknownNCT03992911Phase 2/3
• Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver ResectionSuspendedNCT03990974Phase 3
• PD-L1 and BRAF Expression in Nasopharyngeal CarcinomaCompletedNCT03989297
• Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular CarcinomaStatus unknownNCT03988998Phase 3
• Surgical Management of Multiple Mucoepidermoid Carcinoma and AdenocarcinomaCompletedNCT03988959Not applicable
• Neoadjuvant Nivolumab for Operable Esophageal CarcinomaStatus unknownNCT03987815Phase 2
• Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell CarcinomaStatus unknownNCT03987698Phase 2
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• 68 Ga PSMA PET/MRI for Hepatocellular CarcinomaCompletedNCT03982407Early Phase 1
• A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible TumorsActive, not recruitingNCT03982212Phase 1
• The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma PatientsCompletedNCT03981224
• 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03980288Phase 1
• Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedNCT03980041Phase 2
• Albumin for Hepatocellular CarcinomaStatus unknownNCT03974074Phase 3
• Plasma EBV DNA Monitoring in Post-treatment NPC PatientsCompletedNCT03973723
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Phase 2
• Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.Status unknownNCT03972748Not applicable
• AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03971747Phase 1
• Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant MetastasesTerminatedNCT03970967Not applicable
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2
• Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)Status unknownNCT03969576Not applicable
• Safety and Efficacy of PD-1 Inhibitors in Patients With Liver TransplantStatus unknownNCT03966209Phase 1
• Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing ChemotherapyCompletedNCT03964896Not applicable
• Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary ObstructionCompletedNCT03962478Not applicable
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaActive, not recruitingNCT03961698Phase 2
• A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Phase 3
• Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCCTerminatedNCT03958669
• A Safety Study of SGN-CD47M in Patients With Solid TumorsTerminatedNCT03957096Phase 1
• Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)CompletedNCT03956836
• FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTSCompletedNCT03955393
• Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCCCompletedNCT03953443
• SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant WaitlistStatus unknownNCT03950102Not applicable
• Predictive Value of PET CT in the Histologic Lymph Node Status of Patients With Squamous Cell Carcinoma of the Oral N0 Clinical and Radiological Cavity.Status unknownNCT03947892
• A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery RecurrenceTerminatedNCT03945799Phase 1/2
• Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial CarcinomaSuspendedNCT03945786
• Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)Status unknownNCT03944252Phase 2
• Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)Status unknownNCT03943602Phase 2
• Cell-free Tumor DNA in Head and Neck Cancer PatientsStatus unknownNCT03942380Not applicable
• Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Phase 2
• Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCCompletedNCT03939975Phase 2
• A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor ThrombiStatus unknownNCT03939845Phase 3
• Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell CarcinomaStatus unknownNCT03938012
• Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnNCT03935347Phase 2
• Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal CarcinomaStatus unknownNCT03932266Phase 2
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)CompletedNCT03931304
• MEtatastic Renal Carcinoma LINesStatus unknownNCT03928964
• KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03927495Phase 2
• Liquid Biopsy in Head and Neck CancerStatus unknownNCT03926468
• Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC PatientsStatus unknownNCT03925896Phase 1
• KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedNCT03925870Phase 2
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC PatientsActive, not recruitingNCT03925090Phase 2
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
• Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian CancerTerminatedNCT03922776Not applicable
• Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)Active, not recruitingNCT03921671Phase 2
• Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
• The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Phase 2
• The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular CarcinomaStatus unknownNCT03917017Not applicable
• KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder CancerTerminatedNCT03915405Phase 1
• Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal CarcinomaStatus unknownNCT03915132Phase 2
• A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic ResectionStatus unknownNCT03914352Not applicable
• Apatinib in the Treatment of Recurrence or Metastasis of Esophageal CancerStatus unknownNCT03913182Phase 2
• Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular CarcinomaStatus unknownNCT03908840Phase 1
• Branched-chain Amino Acid Supplementation for Hepatocellular CarcinomaWithdrawnNCT03908255Phase 2
• Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerActive, not recruitingNCT03907527Phase 1
• A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedNCT03906526Phase 1
• Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyCompletedNCT03906058Phase 2
• TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCCStatus unknownNCT03905967Phase 3
• DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal CarcinomaWithdrawnNCT03905902Phase 3
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell CarcinomaTerminatedNCT03905889Phase 1
• Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell CarcinomaCompletedNCT03904927Phase 2
• Application of Watson for Oncology in Hepatocellular Carcinoma SurgeryStatus unknownNCT03904667
• Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisStatus unknownNCT03904225Phase 2
• Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their CaregiversCompletedNCT03902535
• Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaWithdrawnNCT03901378Phase 2
• Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal CarcinomaStatus unknownNCT03900871Early Phase 1
• RFA vs. SBRT for Small HCCStatus unknownNCT03898921Phase 3
• The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
• Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedNCT03893695Phase 1/2
• ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular CarcinomaCompletedNCT03888859Early Phase 1
• Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationCompletedNCT03888092Phase 1/2
• Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Phase 1
• Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular CarcinomaStatus unknownNCT03881501
• By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave AblationStatus unknownNCT03880721
• Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHNCompletedNCT03880396
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1

← Carcinoma overview